Grace Paradela, MD
Internal Medicine · Saint George, UTNPI 1588673826
Payments from drug & device makers
Across 134 payments — averaging $18.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$428
- Johnson & Johnson$235
- Otsuka America Pharmaceutical, Inc.$230
- Boston Scientific$160
- Pfizer$158
- AstraZeneca$139
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,412100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 30 | $428 |
| Johnson & Johnson | 14 | $235 |
| Otsuka America Pharmaceutical, Inc. | 2 | $230 |
| Boston Scientific | 8 | $160 |
| Pfizer | 9 | $158 |
| AstraZeneca(2 entities) | 8 | $139 |
| Amgen(2 entities) | 7 | $131 |
| Novo Nordisk | 8 | $116 |
| Sanofi-aventis U.S. LLC | 5 | $88 |
| Merck | 6 | $84 |
| IBSA Pharma Inc. | 4 | $74 |
| Medtronic(2 entities) | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $51 |
| Inspire Medical Systems, Inc. | 2 | $51 |
| Lucid Diagnostics Inc. | 2 | $50 |
| Boehringer Ingelheim | 3 | $46 |
| Nevro Corp. | 1 | $42 |
| Strongbridge US Inc. | 2 | $37 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Grifols USA, LLC | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Alfasigma USA, Inc. | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Novartis | 1 | $15 |
| Abbott | 1 | $14 |
| Sumitomo Pharma America, Inc. | 2 | $13 |
| Tactile Systems Technology Inc | 1 | $13 |
| GSK | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$230
How this compares
$2,413 in reported general payments places this provider in the 80th percentile of 496 internal medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 128 | $169,871 |
| OzempicSemaglutide | 80 | $89,153 |
| MounjaroTirzepatide | 17 | $29,055 |
| HorizantGabapentin Enacarbil | 12 | $22,806 |
| MyrbetriqMirabegron | 31 | $18,735 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $18,337 |
| JardianceEmpagliflozin | 15 | $16,172 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $9,948 |
| Levothyroxine Sodium | 762 | $8,539 |
| Estradiol | 167 | $7,048 |
| SynthroidLevothyroxine Sodium | 80 | $6,386 |
| Liothyronine Sodium | 113 | $6,369 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $6,068 |
| Omeprazole | 338 | $5,320 |
| Potassium Chloride | 156 | $4,345 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $158 | $169,871128 claims |
| Novo NordiskOzempic | $116 | $89,15380 claims |
| Lilly USA, LLCMounjaro | $16 | $29,05517 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $88 | $18,33712 claims |
| Boehringer IngelheimJardiance | $46 | $16,17215 claims |
| AbbVieSynthroid | $428 | $6,38680 claims |
| GSKAnoro Ellipta | $13 | $6,06812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 496 internal medicine providers in Utah.
Other internal medicine in Saint George
- Joseph WoolleySaint George$3.6M
- Ahad SabetSalt Lake City$34.5M
- Barbara RizzardiSandy$27.8M
- Willard DereSalt Lake City$4.7M
- Justin MansfieldOgden$3.1M
- Michael KillpackSandy$2M
- Cuper Martinez SantibanezWest Valley City$1M
- Joshua OaksBountiful$973K
- Brandon WebbSalt Lake City$544K
- Yong Hui AhnSlc$474K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.